CIP
NVCR icon

Chartwell Investment Partners’s NovoCure NVCR Stock Holding History

Chartwell Investment Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,963
Closed -$344K – 441
2021
Q3 		$344K Hold
2,963
– – 0.01% 422
2021
Q2 		$657K Hold
2,963
– – 0.02% 399
2021
Q1 		$392K Hold
2,963
– – 0.01% 407
2020
Q4 		$513K Sell
2,963
-15,214
-84% -$2.08M 0.02% 402
2020
Q3 		$2.02M Hold
18,177
– – 0.07% 273
2020
Q2 		$1.08M Sell
18,177
-6,629
-27% -$436K 0.04% 323
2020
Q1 		$1.67M Buy
24,806
+2,662
+12% +$210K 0.08% 270
2019
Q4 		$1.87M Buy
+22,144
New +$1.79M 0.06% 295

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Chartwell Investment Partners's NVCR Position: Q4 2021 in Review

Chartwell Investment Partners sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 2,963 shares — an estimated $344K sold.

Chartwell Investment Partners first reported a position in NVCR in Q4 2019 and held it in 8 quarters. The position peaked at $2.02M in Q3 2020. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

  • Chartwell Investment Partners reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
  • Chartwell Investment Partners sold 2,963 NovoCure shares in Q4 2021, an estimated $344K.
  • Chartwell Investment Partners first reported a position in NovoCure in Q4 2019 and held it in 8 quarters.
  • Chartwell Investment Partners's NovoCure position peaked at $2.02M in Q3 2020.
  • 311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on Chartwell Investment Partners's 13F filing for Q4 2021, filed 15 Feb 2022.